Stocks
HSBC Downgrades Amgen from Buy to Hold Due to Fair Value
HSBC has downgraded Amgen from Buy to Hold, citing fair value after re-rating. This change is reflected in the TipRanks Smart Score performance, which is based on backtested results. Backtested performance is not an indicator of future actual results and may have under- or over-compensated for market factors.
The downgrade means that HSBC believes Amgen's current price accurately reflects its value, making it a less attractive investment opportunity. The TipRanks Smart Score uses historical data to construct models that identify profitable trades, but backtested results should be viewed with caution as they do not reflect actual trading or the effect of material economic and market factors.